![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, September 09, 2015 12:51:02 PM
CAESAREA, Israel, Sept. 9, 2015 /PRNewswire/ -- LabStyle Innovations Corp. (DRIO), today announced it has been granted a patent from the U.S. Patent and Trademark Office for U.S. Patent No. 9,125,549 on September 8, 2015. The patent titled, "Fluids Testing Apparatus and Methods of Use" broadens and builds upon the IP rights previously granted to Dario in the U.S. through a patent issued in 2014 that addresses how the Dario™ blood glucose monitor draws power from and transmits data to a smart phone via the audio jack port. The new patent broadens these claims to include testing of other bodily fluids through an audio jack connection.
"This is a very important patent that expands our IP rights in the U.S. beyond the market for glucose monitoring for diabetes to the diagnostics and management for a broad range of health related conditions including other chronic diseases," stated LabStyle President and Chief Executive Officer Erez Raphael. "Through our proprietary technology, we can test bodily fluids including blood, urea and saliva to measure not just glucose but other health indicators as well, all through audio jack connections on smart phones and other digital devices."
The patent comes at an important time, as the Dario has been submitted for marketing clearance to the U.S. Food and Drug Administration through a form 510K. LabStyle anticipates a response from the FDA in the coming months.
According to market research firm Global Data, the use of mobile technology in managing chronic conditions will grow to $8 billion by 2018.
About LabStyle Innovations
LabStyle Innovations Corp. (DRIO) develops and commercializes patented technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario™ Diabetes Management Solution. Dario™ empowers people with diabetes to take charge of their health with the right tools, insights, and support in their pocket. With access to both real-time and historical blood glucose data, Dario™ is designed to spot patterns, recommend the right treatments and support behavior change efforts.
.
.
Related Quotes
.
LS1A.BE
0.00%
DRIO
0.32
-5.33%
LABSTYLE INNOVATNS? Watchlist
0.00(0.00%)
Berlin
.
Dario™ is a platform that combines an all-in-one, blood glucose meter, smart phone application (iOS & Android), website application and treatment tools to support more proactive and better informed decisions by patients, doctors and healthcare systems. The stylish and compact self-monitoring system combines a lancet to obtain a blood sample, a proprietary disposable test strip cartridge and a smartphone-driven glucose meter. LabStyle Innovations is led by an experienced management team with vast software, medical device and technology experience and is guided by a world class board of directors and scientific advisory board. For more information: www.myDario.com and http://myDario.investorroom.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, we are using forward-looking statements in this press release when we discuss the importance of our patent titled "Fluids Testing Apparatus and Methods of Use, the use of mobile technology in managing chronic conditions, the description of the size of the mobile technology market, and the anticipated FDA clearance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Contacts:
Press and Investor Relations
Brenda Zeitlin
LabStyle Innovations
+1-800-896-9062
Brenda@mydario.com
Recent DRIO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:02:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:01:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 12:30:15 PM
- Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer • PR Newswire (US) • 06/05/2024 12:30:00 PM
- DarioHealth Reports First Quarter 2024 Financial and Operating Results • PR Newswire (US) • 05/15/2024 10:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 10:06:09 AM
- DarioHealth to Report First Quarter 2024 Results on Wednesday, May 15th • PR Newswire (US) • 05/07/2024 12:30:00 PM
- Dario Publishes New Peer-Reviewed Study that Deepens the Body of Evidence that Managing Cardiometabolic Conditions in One Integrated Platform Improves Clinical Outcomes • PR Newswire (US) • 04/25/2024 12:30:00 PM
- Dario Signs Two Employers for Cardiometabolic Suite with Integrated GLP-1 Solution • PR Newswire (US) • 04/18/2024 12:30:00 PM
- Dario Publishes Two New Peer-Reviewed Studies Demonstrating Impact of Digital Behavioral Health • PR Newswire (US) • 04/10/2024 12:30:00 PM
- Two National Employers Select Dario's Integrated Chronic Condition Solution to Improve Employee Health • PR Newswire (US) • 04/02/2024 12:30:00 PM
- DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results • PR Newswire (US) • 03/28/2024 10:30:00 AM
- DARIOHEALTH TO REPORT FOURTH QUARTER 2023 RESULTS ON THURSDAY, MARCH 28TH • PR Newswire (US) • 03/21/2024 12:30:00 PM
- New Research from Dario Demonstrates Ability to Deliver Improved Health Outcomes with Integrated Solution for Members Managing Weight and Blood Glucose with or without GLP-1 Medications • PR Newswire (US) • 03/12/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:24:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:23:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:21:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:20:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:19:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:16:57 PM
- DARIOHEALTH TO PARTICIPATE IN THE COWEN 43RD ANNUAL HEALTHCARE CONFERENCE • PR Newswire (US) • 02/28/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:05:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:16:56 PM
ECGI Holdings Announces LOI to Acquire Pacific Saddlery to Capitalize on $12.72 Billion Market Potential • ECGI • Jun 13, 2024 9:50 AM
Fifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates • CAFI • Jun 13, 2024 8:45 AM
Snakes & Lattes Opens Pop-Up Location at The Wellington Market in Toronto: A New Destination for Fun and Games - Thanks 'The Well', PepsiCo, Indie Pale House & All Sponsors & Partners for Their Commitment & Assistance Throughout The Process • FUNN • Jun 13, 2024 8:18 AM
HealthLynked Introduces Innovative Online Medical Record Request Form Using DocuSign • HLYK • Jun 12, 2024 8:00 AM
Ubiquitech Software Corp (OTC:UBQU) Posts $624,585 Quarterly Revenue - Largest Quarter Since 2018 • UBQU • Jun 11, 2024 10:13 AM
Element79 Gold Corp Files for OTCQB Uplisting, Provides Financial Update • ELEM • Jun 11, 2024 9:25 AM